Sino Biopharmaceutical Ltd (HKG: 1177), a major player in the Chinese pharmaceutical industry, announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Novartis’s Revolade (eltrombopag olamine). The drug is indicated for the treatment of adults and children aged six and above with chronic immune (idiopathic) thrombocytopenia (ITP) who have not responded well to prior treatments, such as glucocorticoids and immunoglobulins. Its purpose is to increase platelet count and reduce or prevent bleeding episodes. On the same day, generics from Aosaikang Pharma, Qilu Pharma, and Kelun Pharma also received approval.
Eltrombopag olamine, an oral small-molecule thrombopoietin receptor agonist (TPO-RA), works by increasing the platelet count. The originator drug has received approvals for chronic ITP in both adults and children, as well as for severe aplastic anemia (SAA) patients who have not sufficiently responded to immunosuppressive therapy. Eltrombopag olamine was included in China’s National Reimbursement Drug List (NRDL) in 2019, with two indications covered by the end of 2023.- Flcube.com
